T-Vec: Clinical Trials

9 trials of T-Vec, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 1 withdrawn. 9 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 5, Terminated 3, Withdrawn 1
Phase 21Completed 1

Follow T-Vec: new trials by email Literature Review of T-Vec trials Research Report on T-Vec

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Phase 1CompletedUniversity of California, San Francisco202020-02-052025-05-21
Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin
Panitumumab, Talimogene Laherparepvec - Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Phase 1TerminatedRutgers, The State University of New Jersey52020-01-312026-01-23
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Phase 1TerminatedJonsson Comprehensive Cancer Center62019-07-102023-08-15
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
Capecitabine, Fluorouracil, Leucovorin - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Phase 1TerminatedNational Cancer Institute (NCI)32019-05-142024-05-23
Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Laboratory Biomarker Analysis, Talimogene Laherparepvec - Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Phase 1WithdrawnUniversity of California, San Francisco2018-06-012020-07-28
Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
Talimogene laherparepvec - Pancreatic Cancer
Phase 1CompletedKarie D. Runcie, MD102017-11-162024-11-22
Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Talimogene laherparepvec - Unresectable Stage IIIB-IV Malignant Melanoma
Phase 1CompletedAmgen182017-03-072023-08-09
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Talimogene laherparepvec, Ipilimumab - Melanoma
Phase 1 / Phase 2CompletedAmgen2172013-02-072024-05-14
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
Talimogene Laherparepvec - Pancreatic Cancer
Phase 1CompletedBioVex Limited172006-11-012016-04-15

Conditions studied

Pancreatic Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Breast Carcinoma In Situ (1)  ·  Breast Neoplasms (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Rectal Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Amgen (2)  ·  University of California, San Francisco (2)  ·  BioVex Limited (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Karie D. Runcie, MD (1)  ·  National Cancer Institute (NCI) (1)  ·  Rutgers, The State University of New Jersey (1)

Countries

United States (8)  ·  France (1)  ·  Germany (1)  ·  Japan (1)

Top investigators

Adam C Berger, MD, FACS (1)  ·  Amy J Chien, MD (1)  ·  John A Glaspy (1)  ·  Karie Runcie, MD (1)  ·  Nageshwara V Dasari (1)  ·  Neil N Senzer, MD (1)  ·  Robert Coffin, PhD (1)  ·  Terence Friedlander (1)

Results publications

PMID 37621406, PMID 39673447, PMID 41271741

NIH funding

P30CA072720 (1), UM1CA186688 (1)